New stent method may cut risks and radiation for heart patients
NCT ID NCT06013007
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a new, simpler method called JINS for placing drug-coated stents in heart arteries. Researchers wanted to see if it could help achieve better stent placement while reducing extra radiation and complications from balloon inflation. The study involved 161 people with acute coronary syndrome who needed a stent in a new blockage.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
161 people
The number who actually took part.
- Started
-
Aug 2023
- Finished
-
Mar 2026
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 80 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Patients with acute coronary syndrome (UA/NSTEMI/STEMI) plan to undergo OCT- or IVUS-guided DES implantation in de novo lesion. * Patients provide written informed consent prior to enrollment. Exclusion Criteria: * Left main, ostial right coronary artery lesion. * High thrombus burden at the index primary percutaneous coronary intervention. * Active bleeding or bleeding diathesis, thrombocytopenia (platelet \<100,000/mL), or hemoglobin \<10 g/dL * Hepatic dysfunction (serum liver enzyme\>3 times the normal limit) * Renal failure (eGFR \<15 ml/min/1.73m2 or requiring dialysis) * Life expectancy \< 1 year
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Acute coronary syndrome are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Affiliated Hospital of Zunyi Medical University
Zunyi, Guizhou, 563003, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Tailoring cardiac rehab to each heart: can personalized training speed recovery?
- Can a 20-Minute playlist calm a heart attack Patient's nerves?
- Balloon vs stent: can a Drug-Coated balloon keep large heart arteries open without metal?
- A simple ultrasound test may sharpen heart attack risk predictions
- Could a personal playlist calm nerves during heart surgery?
- Are Europe's heart patients getting the right prevention care? a massive survey aims to find out